Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra1713263
   PubMed Web of Science ®Google Scholar
• Kim BH, Lim YS, Kim EY, et al. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. J Gastroenterol Hepatol. 2018;33(2):475–483. doi:10.1111/jgh.13848
   PubMed Web of Science ®Google Scholar
• Lai Z, He M, Bu X, et al. Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: a biomolecular exploratory, Phase II trial. Eur J Cancer. 2022;174:68–77. doi:10.1016/j.ejca.2022.07.005
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang J, Zhang X, Mu H, Yu G, Xing W. Triple combination therapy comprising angiogenesis inhibitors, anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2021;39(15_suppl):e16124–e16124. doi:10.1200/JCO.2021.39.15_suppl.e16124
   Web of Science ®Google Scholar
• Gu S, Tan Y, Zhou H, et al. Combination of donafenib and anti-PD-1 antibody plus trans-arterial chemoembolization (TACE) in unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2022;40(16_suppl):e16197–e16197. doi:10.1200/JCO.2022.40.16_suppl.e16197
   Google Scholar
• Salem R, Greten TF. Interventional radiology meets immuno-oncology for hepatocellular carcinoma. J Hepatol. 2022. doi:10.1016/j.jhep.2022.08.003
   Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.mct-17-0386
   PubMed Web of Science ®Google Scholar
• Zou Y, Zou X, Zheng S, et al. Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920940928. doi:10.1177/1758835920940928
   Web of Science ®Google Scholar
• Vitale A, Farinati F, Noaro G, et al. Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: a Multicenter Cohort Study. Hepatology. 2018;68(4):1232–1244. doi:10.1002/hep.30185
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636–2646. doi:10.1016/S0140-6736(19)31138-9
   PubMed Web of Science ®Google Scholar
• Ebadi M, Montano-Loza AJ. Clinical relevance of skeletal muscle abnormalities in patients with cirrhosis. Dig Liver Dis. 2019;51(11):1493–1499. doi:10.1016/j.dld.2019.05.034
   PubMedGoogle Scholar
• Nakamura R, Inage Y, Tobita R, et al. Sarcopenia in Resected NSCLC: effect on Postoperative Outcomes. J Thorac Oncol. 2018;13(7):895–903. doi:10.1016/j.jtho.2018.04.035
   PubMed Web of Science ®Google Scholar
• Berardi G, Antonelli G, Colasanti M, et al. Association of Sarcopenia and Body Composition With Short-term Outcomes After Liver Resection for Malignant Tumors. JAMA Surg. 2020;155(11):56.
   Web of Science ®Google Scholar
• Miyamoto Y, Baba Y, Sakamoto Y, et al. Sarcopenia is a Negative Prognostic Factor After Curative Resection of Colorectal Cancer. Ann Surg Oncol. 2015;22(8):2663–2668. doi:10.1245/s10434-014-4281-6
   PubMed Web of Science ®Google Scholar
• Yang J, Chen K, Zheng C, et al. Impact of sarcopenia on outcomes of patients undergoing liver resection for hepatocellular carcinoma. J Cachexia Sarcopenia Muscle. 2022;13(5):2383–2392. doi:10.1002/jcsm.13040
   PubMed Web of Science ®Google Scholar
• Loosen SH, Schulze-Hagen M, Bruners P, et al. Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies. Cancers. 2019;11(10):1503.
   PubMed Web of Science ®Google Scholar
• Uojima H, Chuma M, Tanaka Y, et al. Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer. 2020;9(2):193–206. doi:10.1159/000504604
   PubMed Web of Science ®Google Scholar
• Kuo MH, Tseng CW, Hsu CS, et al. Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: a Systematic Review and Meta-Analysis. Cancers. 2023;15(9):67.
   Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601. doi:10.1093/ageing/afz046
   PubMed Web of Science ®Google Scholar
• Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020;21(3):300–307 e302. doi:10.1016/j.jamda.2019.12.012
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Shiraki M, Hiramatsu A, Moriya K, Hino K, Nishiguchi S. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol Res. 2016;46(10):951–963. doi:10.1111/hepr.12774
   PubMed Web of Science ®Google Scholar
• Yamasaki T, Saeki I, Yamauchi Y, et al. Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. Liver Cancer. 2022;11(4):329–340. doi:10.1159/000522389
   PubMed Web of Science ®Google Scholar
• Kkf C, Mitchell SA, Chan N, Ang E, Tam W, Kanesvaran R. Linguistic validation of the simplified Chinese version of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). BMC Cancer. 2020;20(1):1153. doi:10.1186/s12885-020-07631-5
   PubMed Web of Science ®Google Scholar
• Hiraoka A, Kumada T, Kariyama K, et al. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: analysis adjusted with inverse probability weighting. J Gastroenterol Hepatol. 2021;36(7):1812–1819. doi:10.1111/jgh.15336
   PubMed Web of Science ®Google Scholar
• Saeki I, Yamasaki T, Maeda M, et al. No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. Liver Cancer. 2018;7(4):359–371. doi:10.1159/000487858
   PubMed Web of Science ®Google Scholar
• Antonelli G, Gigante E, Iavarone M, et al. Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment. United Eur Gastroenterol J. 2018;6(7):1039–1048. doi:10.1177/2050640618781188
   PubMed Web of Science ®Google Scholar
• Guan J, Yang Q, Chen C, Wang G, Zhu H. Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: a meta-analysis. EXCLI J. 2021;20:1–16. doi:10.17179/excli2020-3111
   PubMed Web of Science ®Google Scholar
• Toshida K, Itoh S, Tomiyama T, et al. Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients. JGH Open. 2022;6(7):477–486. doi:10.1002/jgh3.12777
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Tsuchiya K, Nakanishi H, et al. Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers. 2022;14(14):454.
   PubMed Web of Science ®Google Scholar
• Guo Y, Ren Y, Wu F, Dong X, Zheng C. Prognostic impact of sarcopenia in patients with hepatocellular carcinoma treated with PD-1 inhibitor. Therap Adv Gastroenterol. 2022;15:17562848221142417. doi:10.1177/17562848221142417
   Web of Science ®Google Scholar
• Akce M, Liu Y, Zakka K, et al. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody. Am J Clin Oncol. 2021;44(2):74–81. doi:10.1097/COC.0000000000000787
   PubMed Web of Science ®Google Scholar
• Ke Q, Xin F, Fang H, Zeng Y, Wang L, Liu J. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: a Systematic Review. Front Immunol. 2022;13:913464. doi:10.3389/fimmu.2022.913464
   PubMed Web of Science ®Google Scholar
• Xin Y, Cao F, Yang H, et al. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Front Immunol. 2022;13:929141. doi:10.3389/fimmu.2022.929141
   PubMed Web of Science ®Google Scholar
• Jorgensen JT. Companion and Complementary Diagnostics: clinical and Regulatory Perspectives. Trends Cancer. 2016;2(12):706–712. doi:10.1016/j.trecan.2016.10.013
   PubMed Web of Science ®Google Scholar
• Takenaka Y, Oya R, Takemoto N, Inohara H. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis. J Cachexia Sarcopenia Muscle. 2021;12(5):1122–1135. doi:10.1002/jcsm.12755
   PubMed Web of Science ®Google Scholar
• Fu Y, Peng W, Zhang W, et al. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J Gastroenterol. 2023;58(4):413–424. doi:10.1007/s00535-023-01976-x
   PubMed Web of Science ®Google Scholar
• Yu W, Liu W, Zhang K, Chen S, Wang X. Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective study. Cancer Immunol Immunother. 2023;72(11):3609–3619. doi:10.1007/s00262-023-03511-6
   PubMed Web of Science ®Google Scholar
• Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015;7(4):17–29. doi:10.4251/wjgo.v7.i4.17
   PubMed Web of Science ®Google Scholar
• C-H W, Liang P-C, Hsu C-H, Chang F-T, Shao -Y-Y, Ting-Fang Shih T. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma. JFormos Med Assoc. 2021;120(1, Part 2):559–566. doi:10.1016/j.jfma.2020.07.005
   PubMed Web of Science ®Google Scholar
• Saeki I, Yamasaki T, Yamauchi Y, et al. Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. Cancers. 2021;13(9):2247.
   PubMed Web of Science ®Google Scholar
• Dasarathy S. Consilience in sarcopenia of cirrhosis. J Cachexia Sarcopenia Muscle. 2012;3(4):225–237. doi:10.1007/s13539-012-0069-3
   PubMed Web of Science ®Google Scholar
• Dalamaga M. Interplay of adipokines and myokines in cancer pathophysiology: emerging therapeutic implications. World J Exp Med. 2013;3(3):26–33. doi:10.5493/wjem.v3.i3.26
   PubMedGoogle Scholar
• Waldmann TA, Dubois S, Miljkovic MD, Conlon KC. IL-15 in the Combination Immunotherapy of Cancer. Front Immunol. 2020;11:868. doi:10.3389/fimmu.2020.00868
   PubMed Web of Science ®Google Scholar
• Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin Cancer Res. 2010;16(24):6019–6028. doi:10.1158/1078-0432.CCR-10-1966
   PubMed Web of Science ®Google Scholar
• Chen BB, Liang PC, Shih TT, et al. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma. Eur Radiol. 2023;33(1):512–522. doi:10.1007/s00330-022-08980-4
   PubMed Web of Science ®Google Scholar
• Kim N, Yu JI, Park HC, et al. Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab. Cancer Immunol Immunother. 2021;70(6):1593–1603. doi:10.1007/s00262-020-02794-3
   PubMed Web of Science ®Google Scholar